Management of Atrial Fibrillation after CRT-P Placement
Clinical Decision Framework
- The American College of Cardiology and the American Heart Association recommend beta-blockers as the first-line agents for rate control in patients with heart failure and AF, with digoxin added for resting heart rate control if necessary 1, 2
- A combination of digoxin plus beta-blocker is reasonable for controlling both resting and exercise heart rates in patients with heart failure and AF 1, 2
- Amiodarone should be reserved for specific scenarios, such as when beta-blockers and digoxin fail to adequately control heart rate, or when rhythm control is indicated in patients with heart failure 1, 2
Rhythm Control Strategies
- The European Society of Cardiology suggests that amiodarone offers distinct advantages over other antiarrhythmic agents when rhythm control is chosen in patients with heart failure 3, 4, 5
- Amiodarone can be effective for rhythm control in patients with heart failure, with low-dose amiodarone (200 mg daily or less) potentially having fewer side effects 3, 4, 5
Safety Considerations
- The American College of Cardiology recommends that amiodarone should only be used cautiously as a first-line agent due to its significant extracardiac toxicity profile, with 18% of patients discontinuing amiodarone due to side effects after a mean of 468 days 3, 6, 7